PMC:7600245 / 35158-35420
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T129 | 167-175 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T130 | 176-185 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T532 | 85-87 | Chemical | denotes | NA | http://purl.obolibrary.org/obo/CHEBI_33696 |
| T533 | 93-114 | Chemical | denotes | neuroprotective agent | http://purl.obolibrary.org/obo/CHEBI_63726 |
| T534 | 132-145 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
| T535 | 230-239 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T259 | 0-262 | Sentence | denotes | Currently, it is being evaluated alone (NCT04468087; n = 189) or in combination with NA-831 (neuroprotective agent; traneurocin) or dexamethasone for the treatment of COVID-19 infection (NCT04452565; n = 525) or with nitazoxanide/ritonavir (NCT04459286; n = 98). |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1065 | 85-91 | Chemical | denotes | NA-831 | |
| 1066 | 116-127 | Chemical | denotes | traneurocin | |
| 1067 | 132-145 | Chemical | denotes | dexamethasone | MESH:D003907 |
| 1068 | 217-239 | Chemical | denotes | nitazoxanide/ritonavir | |
| 1074 | 167-175 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1075 | 176-185 | Disease | denotes | infection | MESH:D007239 |